Declaration of Interest



A. General Information

Full Name: Peter Jüni

Date (MM/DD/YYYY): 5/12/2021

What is the nature of your role in the Drugs & Biologics Clinical Practice Guidelines Working Group: Member

B. Declaration of Interest

Please fill out the following table by indicating whether you or your institution have received compensation, regardless of the amount, in the form of payment or services, from entities in the health care, public health, or other related arenas that could be perceived to influence your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group, or related aspects. Please report all compensation that has been received in the last 3 years prior to your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group.

If you have selected 'Yes' for any of the categories below, please indicate whether the compensation is related to COVID-19 or not, the name of the entity providing the compensation, and an explanation. If you have more than one relationship for each Category, please ensure to include all of them by selecting the '+' sign at the end of each row.

Category	No	Yes,	Yes, paid to your	Related to COVID-19?		Entity	Explanation
		you	institution	No	Yes	,	
Grant				\boxtimes		Canadian Institutes of Health Research (CIHR)	Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases
Grant			X		\boxtimes	Appili Therapeutics	Control of COVID-19 outbreaks in long term care with Favipiravir (CONTROL-COVID- Favipiravir). Co-PI.
Grant			\boxtimes	\boxtimes		Astra Zeneca	Cardiovascular research
Grant			\boxtimes	\boxtimes		Biotronik	Cardiovascular research
Grant			\boxtimes	\boxtimes		Biosensors International	Cardiovascular research
Grant			\boxtimes	\boxtimes		Eli Lilly	Cardiovascular research
Grant			\boxtimes	\boxtimes		The Medicines Company	Cardiovascular research
Grant			×	\boxtimes		Canadian Institutes of Health Research	TRICS IV - Restrictive versus Liberal Transfusion in Younger Patients Undergoing Cardiac Surgery
Grant			×		\boxtimes	Various, non- commercial	Coagulopathy of COVID- 19: a Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care. Co-PI.

Grant		\boxtimes		\boxtimes	University of Toronto	Prone positioning for patients on general medical wards with COVID19: A multicenter pragmatic randomized trial. Co-Applicant.
Grant					CIHR Grant + U of T	Careful Ventilation in COVID 19 –induced ARDS - The CAVIARDS 19 Trial. Co-Applicant.
Grant		\boxtimes		\boxtimes	University of Toronto	Control of COVID-19 outbreaks in long term care. Co-PI.
Grant		×		\boxtimes	Canadian Institutes of Health Research (CIHR), Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics	Semaglutide to reduce Myocardial injury in patients with COVID-19 (SEMPATICO): An exploratory randomized controlled clinical trial. Co-Applicant.
Grant				×	Canada: CIHR-SPOR	REMAP-CAP: a platform trial for severely ill patients with COVID-19 / REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia. Co-Applicant.
Grant		\boxtimes	\boxtimes		Canada Foundation for Innovation (CFI), John R. Evans Leaders Fund	The CardioLink Research Platform: Innovations in Cardiovascular Surgery & Cardiometabolic Care
Grant			×		Canadian Institutes of Health Research	The Functional Improvement Trajectories After Surgery (FIT After Surgery) Study: A Multicentre Prospective Cohort Study to Evaluate the Incidence, Trajectories, Risk Factors, Impact and Healthcare Costs
Grant					Canada Foundation for Innovation, Operating Grant: SPOR Innovative Clinical Trial Multi-Year Grant	Evaluating Innovative Health Care Solutions to Improve Outcomes for Persons with Type 1 Diabetes using a Novel Electronic Data Repository Reducing Diabetic Foot Complications through a

					I		
							Multidisciplinary Chiropodist Based Intervention
Grant			\boxtimes			Arthritis Society. Young Investigator Operating Grant	Personalization of osteoarthritis care using large-scale randomized evidence: network meta-analysis and methodological development
Grant			×		×	Canadian Institutes of Health Research.	Operating Grant: COVID-19 Rapid Research Funding Opportunity Title: COVID-19 Ring- based Prevention trial with Lopinavir-ritonavir (CORIPREV-LR).
Consulting			\boxtimes	\boxtimes		Amgen	Honoraria to the institution for participation in advisory board
Consulting			\boxtimes	\boxtimes		Ava	Honoraria to the institution for participation in advisory board
Consulting			\boxtimes	\boxtimes		Fresenius	Honoraria to the institution for participation in advisory board
Board membership	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Employment	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Payment for lectures including service on speaker bureaus		\boxtimes		\boxtimes		Interaction 2019	Interaction 2019 speaker honorarium Sept 21, 2019 ('clinical research' talk)
Payment for manuscript preparation	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Patents	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Royalties	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Payment for development of educational presentations	\boxtimes					Click or tap here to enter text.	Click or tap here to enter text.
Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like						Click or tap here to enter text.	Click or tap here to enter text.
Payment for writing or reviewing any reports or publications						Click or tap here to enter text.	Click or tap here to enter text.

Provision of writing assistance, equipment, software, or administrative support				Click or tap here to enter text.	Click or tap here to enter text.
Expert testimony	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Stock/stock options	\boxtimes			Click or tap here to enter text.	Click or tap here to enter text.
Support for travel/accommodations/ meeting expenses		\boxtimes	\boxtimes	Amgen	Travel expenses for participation in advisory board meetings
Support for travel/accommodations/ meeting expenses		\boxtimes	\boxtimes	Fresenius	Travel expenses for participation in advisory board meetings

C. Other Relationships

Are there any other relationships or activities that could be perceived to influence your participation in the Drugs & Biologics Clinical Practice Guidelines Working Group (COVID-19 related or not)? Please select one of the following:

- ⊠ No, there are no other relationships/conditions/circumstances that present, or may be perceived to present, a potential conflict of interest.
- ☐ Yes, there are relationships/conditions/circumstances that present, or may be perceived to present, a potential conflict of interest.

If you have selected 'Yes', use the following table to indicate whether the relationship is related to COVID-19 or not, provide the name of the entity (if applicable), and an explanation describing the nature of the relationship. If you have more than one relationship, please ensure to include all of them by selecting the '+' sign at the end of each row.

Category	110101	ed to D-19?	. Entity	Explanation	
5	No	Yes			
Relationship	\boxtimes		Abbott Vascular	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		Astra Zeneca	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		Biotronic	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		Biosensors	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		St. Jude Medical	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		Terumo	Unpaid member of steering group or executive committee of trials	
Relationship	\boxtimes		The Medicines Company	Unpaid member of steering group or executive committee of trials	

D. Acknowledgement

I certify that the above information contained in this Declaration of Interest is true and correct to the best of my knowledge. If any matter that gives rise to, or may be perceived to give rise to, a conflict of interest during my participation

in the Drugs & Biologics Clinical Practice Guidelines Working Group, I will promptly notify the co-Chairs of the Drugs & Biologics Clinical Practice Guidelines Working Group, and provide an updated Declaration of Interest.

Full Name: Peter Jüni

Date (MM/DD/YYYY): 5/12/2021